News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ryogen LLC Licenses Human Aminopeptidase P Gene Patent To Invitrogen Corporation (IVGN)


1/9/2007 11:50:15 AM

SUFFERN, N.Y., Jan. 9 /PRNewswire/ -- Ryogen LLC headquartered in Suffern, NY announced today that the company have entered into a nonexclusive license agreement with Invitrogen Corporation headquartered in Carlsbad, CA, whereby Invitrogen has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.

The US Patent No. 6,399,349 titled "Human Aminopeptidase P Gene," which is the subject of the License Agreement, covers the XPNPEP2 gene sequenced by Dr. James Ryan, Chief Scientist of Ryogen LLC. XPNPEP2 codes for the membrane- bound aminopeptidase P (AmP). This protein is a significant marker for hypertension, angioedema, rejection of kidney transplants, certain tumors and other diseases. The patent covers the cDNA and gDNA sequences encoding AmP, a method of producing recombinant AmP, diagnostics for detecting AmP abnormalities, and prevention and treatment of medical conditions, associated with the mutation of the AmP gene.

"We are happy to extend a license under the AmP Patent to Invitrogen," said Valeria Poltorak, Ryogen's Executive Vice President. "We look forward to working with Invitrogen on making this discovery available to the research community," she concluded.

About Ryogen, LLC

Ryogen, LLC is a genetic company that is the owner of United States Patent No. 6,399,349 titled "Human Aminopeptidase P Gene" as well as 17 patent applications. Patent applications currently pending before the US Patent and Trademark Office are directed to other genes, playing important roles in various cancers, diabetes and obesity, hepatitis C, atherosclerosis, Alzheimer's and several other diseases. Ryogen is a portfolio company of IP Holdings LLC, an idea incubator headquartered in Suffern NY. Ryogen offers nonexclusive licenses under the AmP patent and patent applications to the research community on attractive terms. For licensing terms, contact Valeria Poltorak, Ryogen's Vice President, at (845) 368-4000 ext. 111. For more information about Ryogen visit http://www.ryogen.com.

IP Holdings LLC (IPH) is an idea incubator affiliated with General Patent Corporation International (GPCI), a leading patent licensing firm (http://www.gpci.com). IPH invests in, develops, incubates, and assists in the commercialization of novel and promising technology, with a particular emphasis on the development and protection of intellectual property. For more information about IPH visit http://www.ip-holdings.com.

Ryogen, LLC

CONTACT: Valeria Poltorak of Ryogen LLC, +1-845-368-4000, ext. 111,valeria@ryogen.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES